A Randomized Study of the Site for Growth Factor Injection for Patients Undergoing Autologous Stem Cell Transplantation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00646763|
Recruitment Status : Terminated (Accrual goal met)
First Posted : March 28, 2008
Results First Posted : May 11, 2012
Last Update Posted : December 20, 2013
- Study Details
- Tabular View
- Study Results
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Cytokines||Drug: G-CSF, GM-CSF administered at extremities Drug: G-CSF and GMCSF administered at abdomen||Phase 2|
The purpose of this study is to determine the preferred injection site for G-CSF and GM-CSF, which are cytokines, or growth factors. The doctor may also choose to use these growth factors in combination with chemotherapy to increase the number of stem cells in the blood. Both options are established and are effective in increasing the number of stem cells in the blood.
Patients will receive one shot under the skin twice a day for approximately 12-15 days after receiving chemotherapy through the time your cells are being collected. Patients will be randomly assigned to receive growth factors administered either to their abdomen or to their extremities. Both shots will always be given either in the abdomen or in the extremities.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||35 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Single Institution Randomized Study Comparing Cytokine Administration Sites for Mobilization of Peripheral Hematopoietic Progenitor Cells for Patients Undergoing Autologous Hematopoietic Progenitor Cell Transplant|
|Study Start Date :||April 2008|
|Actual Primary Completion Date :||September 2009|
|Actual Study Completion Date :||February 2011|
Active Comparator: Abdomen
These subjects will have their cytokine injections administered only to their abdomen.
Drug: G-CSF and GMCSF administered at abdomen
Injection site Abdomen: G-CSF injections will commence on the day after completion of mobilization chemotherapy, at least 24 hours after completion of the last chemotherapy dose. On the seventh day of cytokine administration, GMCSF injections will be started, and patients will maintain a BID schedule of G-CSF/GM-CSF until stem cell collection is complete.
Other Name: Neupogen, Leukine, growth factors
Active Comparator: Extremities
The extremity arm will have their injections administered to their upper and/or lower extremities.
Drug: G-CSF, GM-CSF administered at extremities
Injection site Extremities: G-CSF injections will commence on the day after completion of mobilization chemotherapy, at least 24 hours after completion of the last chemotherapy dose. On the seventh day of cytokine administration, GMCSF injections will be started, and patients will maintain a twice daily schedule of G-CSF/GM-CSF until stem cell collection is complete.
Other Name: Neupogen, Leukine, growth factors
- The Total Number of CD34+ Cells Collected. [ Time Frame: 4 days ]
- Number of Participants for Whom Target Number of CD34+ Cells Were Collected. [ Time Frame: 7 days ]Target numbers of CD34+ cells for a single autologous transplant are typically at least 5.0 * 10^6 cells/kg, a cell dose that consistently results in rapid cell engraftment
- Total Number of Days of Apheresis [ Time Frame: 7 days ]the number of days of apheresis required to collect target numbers of CD34+ cells.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- All patients undergoing autologous peripheral blood stem cell transplant (PBSC) for relapsed/refractory Hodgkin's disease, non-Hodgkin's lymphoma, or patients with myeloma. All patients must meet criteria for transplantation.
- Patients with active, invasive/systemic fungal infection.
- Patients who are pregnant or lactating females.
- Patients with active CNS malignant disease or life expectancy limited by diseases other than the disease for which the patient is being transplanted.
- Also, patients cannot have known hypersensitivity to either G-CSF or GM-CSF.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00646763
|United States, Georgia|
|Emory University Winship Cancer Institute|
|Atlanta, Georgia, United States, 30322|
|Principal Investigator:||Edmund Waller, MD||Emory University Winship Cancer Institute|
|Responsible Party:||Edmund Waller, Principal Investigator, Emory University|
|Other Study ID Numbers:||
7445 ( Other Identifier: Other )
|First Posted:||March 28, 2008 Key Record Dates|
|Results First Posted:||May 11, 2012|
|Last Update Posted:||December 20, 2013|
|Last Verified:||November 2013|
Physiological Effects of Drugs
Molecular Mechanisms of Pharmacological Action